Pre-made Tabituximab Barzuxetan benchmark antibody (Whole mAb ADC, anti-FZD10 therapeutic antibody, Anti-CD350/FZ-10/Fz10/FzE7/hFz10 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-1001
Pre-made Tabituximab Barzuxetan benchmark antibody (Whole mAb ADC, anti-FZD10 therapeutic antibody, Anti-CD350/FZ-10/Fz10/FzE7/hFz10 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-INN-1001-1mg | 1mg | Inquiry | ||
GMP-Bios-INN-1001-10mg | 10mg | Inquiry | ||
GMP-Bios-INN-1001-100mg | 100mg | Inquiry | ||
GMP-Bios-INN-1001-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Tabituximab Barzuxetan Biosimilar, Whole Mab Adc, Anti-Fzd10 Antibody: Anti-CD350/FZ-10/Fz10/FzE7/hFz10 therapeutic antibody Drug Conjugate |
INN Name | Tabituximab Barzuxetan |
Target | FZD10 |
Format | Whole mAb ADC |
Derivation | Chimeric |
Species Reactivity | human |
CH1 Isotype | IgG1 - kappa |
VD LC | IgG1 - kappa |
Highest_Clin_Trial (Jan '20) | |
Est. Status | |
100% SI Structure | |
99% SI Structure | |
95-98% SI Structure | |
Year Proposed | |
Year Recommended | |
Companies | OncoTherapy Science Inc. (Kawasaki Japan) |
Conditions Approved | |
Conditions Active | |
Conditions Discontinued | |
Development Tech | 0 |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<